Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy

Urology

Volumn 47, Issue 3, 1996, Pages 305-310

  Wu, Catherine S ^a   Pollack, Alan ^a   Czerniak, Bogdan ^a   Chyle, Valerian ^a   Zagars, Gunar K ^a   Dinney, Colin P N ^a   Hu, Shi Xue ^a   Benedict, William F ^a  

^a Box 97 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLADDER BIOPSY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0029922215     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80443-9     Document Type: Article

References (25)

1. Dulic V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
2. Lowe SW, Ruley HE, Jacks J, and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
3. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, and Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53: 3667-3669, 1993.
4. McIlwrath AJ, Vasey PA, Ross GM, and Brown R: Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722, 1994.
5. Baird DS, Martin M, Rhun YL, Duthu A, Lefaix JL, May E, and May P: Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 54: 3361-3364, 1994.
6. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
7. Wilson GD, Richman PI, Dische S, Sanders MI, Robison B, Daley FM, and Ross DA: p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 71: 1248-1252, 1995.
8. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, and Pellicer A: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-353, 1994.
9. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, and Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53-59, 1993.
10. Kuczyk MA, Serth J, Hervatin C, Arndt H, Derendorf L, Thon WF, and Jonas U: Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications. World J Urol 12: 345-351, 1994.
11. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, and Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264, 1994.
12. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 53: 365-370, 1993.
13. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, and Scher HI: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13: 1384-1390, 1995.
14. Pollack A, Zagars GK, Dinney CP, Swanson DA, and von Eschenbach AC: Preoperative radiotherapy for muscle-invasive bladder cancer. Long term follow-up and prognostic factors for 338 patients. Cancer 74: 2819-2827, 1994.
15. Mostofi FJ, Sobin LH, and Torlain H: Histological Typing of Urinary Bladder Tumors. Geneva, World Health Organization, 1973.
16. Beahrs OH, and Myers MH (Eds): Manual for Staging of Cancer, 2nd ed. American Joint Committee on Cancer. Philadelphia, JB Lippincott, 1983, pp 171-173.
17. Vojtesek B, Bartek J, Midgley CA, and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244, 1992.
18. Meyn RE, Milas L, and Stephens LC: Programmed cell death in normal development and disease. Cancer Bull 46: 120-124, 1994.
19. Chyle V, Pollack A, Czerniak BA, Stephens LC, Zagars GK, Terry NHA, and Meyn RE: Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 1995 (in press).
20. Altman DG: Practical Statistics for Medical Research. London: Chapman and Hall, pp 179-268.
21. Harris EK, and Albert A: Survivorship Analysis for Clinical Studies. New York, Marcel Dekker, 1991, pp 5-125.
22. Bryson MC, and Johnson ME: The incidence of monotone likelihood in the Cox model. Technometrics 23: 381-383, 1981.
23. Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A, and Dimopoulos C: Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 46: 334-340, 1995.
24. Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, and von Eschenbach AC: Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 32: 331-340, 1995.
25. Pollack A, Zagars GK, Cole CH, Dinney CP, Swanson DA, and Grossman HB: The relationship of local control to distant metastasis in muscle-invasive bladder cancer. J Urol 154: 2059-2063, 1995.